X4 PHARMACEUTICALS, INC
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 |
|---|---|---|---|
| Revenue | $0 | — | — |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $20.3M | $17.1M | $17.8M |
| SG&A Expense | $8.7M | $5.2M | $6.5M |
| Operating Income | $-29.1M | $-22.2M | $-24.3M |
| Operating Margin | — | — | — |
| Interest Expense | $720.0K | $490.0K | $2.5M |
| Pretax Income | $-33.3M | $-22.0M | $-23.0M |
| Income Tax Expense | $0 | — | — |
| Net Income | $-33.3M | $-22.0M | $-23.0M |
| Net Margin | — | — | — |
| EPS (Basic) | $-6.60 | $-4.55 | $-3.73 |
| EPS (Diluted) | $-6.60 | $-4.55 | $-3.73 |
| Shares Outstanding (Basic) | 4.2M | 171.5M | — |
| Shares Outstanding (Diluted) | 4.2M | 171.5M | — |
| Dividends Per Share | — | — | — |